STOCK TITAN

NeuroSense Therapeutics Ltd. - $NRSN STOCK NEWS

Welcome to our dedicated page for NeuroSense Therapeutics Ltd. news (Ticker: $NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics Ltd.'s position in the market.

Rhea-AI Summary

NeuroSense Therapeutics (NASDAQ: NRSN) announced that its VP of R&D, Dr. Shiran Zimri, will present at the 3rd Annual ALS Drug Development Summit in Boston on May 22, 2024. Dr. Zimri will discuss the potentials of combination therapy in ALS and share the latest progress on PrimeC, NeuroSense's investigational treatment. Recent results from the phase 2b PARADIGM trial showed a 43% slowing of disease progression in high-risk ALS patients treated with PrimeC compared to placebo over 6 months, with a significant 5.04-point difference in ALSFRS-R scores.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences
-
Rhea-AI Summary

NeuroSense Therapeutics (Nasdaq: NRSN) has partnered with PhaseV to optimize its Phase 3 trial of PrimeC for ALS using advanced causal machine learning. PhaseV's analysis of NeuroSense's PARADIGM Phase 2b study predicted high success probabilities in multiple subgroups for the Phase 3 trial. PhaseV's insights will inform study design, patient enrollment, and cost-effectiveness. NeuroSense’s recent Phase 2b data showed PrimeC slowed disease progression by 37% and 43% in high-risk patients. The company plans to submit its End of Phase 2 package to the FDA and EMA soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
partnership clinical trial
-
Rhea-AI Summary

NeuroSense Therapeutics announces positive data analysis from the PARADIGM clinical trial, showing a 43% slowing of disease progression in high-risk ALS patients treated with PrimeC. The study demonstrated consistent results across subgroups, indicating the potential of PrimeC to redefine ALS treatment. The CEO expressed optimism and highlighted the significant impact of PrimeC on patients, with plans to use the data for the upcoming pivotal trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
Rhea-AI Summary

NeuroSense Therapeutics (Nasdaq: NRSN) provides a business update for Q1 2024, highlighting key collaborations and positive results from the PARADIGM Study in ALS and Alzheimer's disease. The company is focused on advancing its treatments for neurodegenerative diseases, with plans for further research and clinical trials in the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics and Genetika+ collaborate in a precision medicine initiative focusing on Alzheimer's Disease. The partnership aims to enhance drug development by utilizing advanced technology for patient-specific neuronal analysis. NeuroSense's innovative PrimeC therapy targets multiple disease-related pathologies, offering a promising approach to AD treatment. The ongoing Phase 2 clinical trial at Rambam Health Care Campus will evaluate PrimeC's therapeutic potential in mild to moderate AD patients over 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics presents positive data validating Phase 2b topline readout during an Emerging Science presentation at the American Academy of Neurology Annual Meeting. The PARADIGM study of PrimeC for Amyotrophic Lateral Sclerosis showed positive clinical effects and a trend towards impacting Neurofilament biomarker levels. PrimeC demonstrated safety, tolerability, and a 37% slowing of disease progression in the per-protocol population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
Rhea-AI Summary
NeuroSense Therapeutics announces the presentation of data from the PARADIGM Phase 2 study of PrimeC for Amyotrophic Lateral Sclerosis at the American Academy of Neurology Annual Meeting. The study met primary and secondary endpoints, highlighting positive outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
-
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) announced a securities purchase agreement with a health-care focused institutional investor for the sale of 2,980,000 shares and warrants at $1.50 per share. The offering includes ordinary warrants with an exercise price of $1.50 per share, exercisable immediately and expiring in 5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
-
Rhea-AI Summary
NeuroSense collaborates with Lonza to advance neurodegenerative disease treatments by utilizing Neuron-Derived Exosomes. Positive Phase 2b PARADIGM trial results for PrimeC in ALS patients. Lonza's 'Dev-on-Demand' solution offers rapid access to expert scientists and laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) reported positive clinical results from the Phase 2b ALS trial, showing a 37.4% slowing of disease progression in patients treated with PrimeC. Financially, the company saw an increase in research and development expenses but a decrease in general and administrative expenses, with cash of $2.6 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.48%
Tags
NeuroSense Therapeutics Ltd.

Nasdaq:NRSN

NRSN Rankings

NRSN Stock Data

20.31M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa